Global Orally Administered Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Orally Administered Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
Orally Administered Vaccine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Orally Administered Vaccine market is projected to reach US$ 3746.5 million in 2029, increasing from US$ 2540 million in 2022, with the CAGR of 5.7% during the period of 2024 to 2029. Demand from Public and Private are the major drivers for the industry.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Orally Administered Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other
Public
Private
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Orally Administered Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Orally Administered Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Orally Administered Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Orally Administered Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Orally Administered Vaccine introduction, etc. Orally Administered Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Orally Administered Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Orally Administered Vaccine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Orally Administered Vaccine market is projected to reach US$ 3746.5 million in 2029, increasing from US$ 2540 million in 2022, with the CAGR of 5.7% during the period of 2024 to 2029. Demand from Public and Private are the major drivers for the industry.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Orally Administered Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other
Segment by Application
Public
Private
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Orally Administered Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Orally Administered Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Orally Administered Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Orally Administered Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Orally Administered Vaccine introduction, etc. Orally Administered Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Orally Administered Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.